Patent 12071482 was granted and assigned to Momenta Pharmaceuticals on August, 2024 by the United States Patent and Trademark Office.
The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.